The Food and Drug Administration, the federal agency that approves new prescription drugs, medical devices, and food safety standards before they reach consumers, is close to getting a new leader. The White House has received a short list of finalists and is in the final stages of deciding who fills the post, according to a person familiar with the selection process. Three candidates are under active review.
The three names in contention
Heidi Overton, a White House adviser, is one finalist. Jeffrey Vacirca, an oncologist and health system executive, is another. The third is Stephen Ferrara, a health affairs official at the Department of Defense. The person who described the list was not identified by name.
The three come from different corners of the health and policy world. Overton works inside the current White House structure. Vacirca's career spans clinical medicine and health system leadership. Ferrara sits in the Defense Department's health affairs office, which oversees medical services for military personnel and their families.
Why FDA leadership draws close attention
Commissioner is the formal title for the person who runs the FDA. The agency reviews applications for new drugs and medical devices, sets standards for how clinical trials must be conducted, and oversees safety rules for the national food supply. Each of those functions touches both public health and large commercial markets.
A commissioner's priorities shape how quickly new treatments reach patients and how strictly existing rules are applied. Different professional backgrounds tend to emphasize different things. A clinician may weigh patient safety endpoints one way, while someone from a defense health administration background may approach institutional process differently. Analysts and advocacy groups watch those distinctions carefully when a nominee emerges.
The White House has not publicly confirmed the list or announced a timeline. The reporting rests on a single unnamed person familiar with the process.